Table 1. Clinical data of the CCR2^high and CCR2^low patients.

206 newly-diagnosed patients with MM were separated into 2 subgroups according to CCR2 gene expression in myeloma cells in order to optimize the difference in patients’ proportion with major structural damage or > osteolyses using the Maxstat package. The 2 subgroups represent patients with high (i.e. CCR2 signal > 3735, CCR2^high) or low (i.e. CCR2 signal ≤ 3735, CCR2^low) CCR2 expression. Data are the percentages of patients within each subgroup with the indicated clinical or biological parameter.

Categories	CCR2^high (n=29)	CCR2^low (n=177)
	% of patients in each subgroup
Bone lesions: Major structural damage or >3 osteolyses	*55%^	*36%^	*P = .03*
Age ≥ 65 yr	21%	19%	NS
Kappa light chain	64%	64%	NS
Lambda light chain	36%	34%	NS
Non-secreting	0%	2%	NS
IgA subtype	21%	25%	NS
B2M ≤ 3.5 mg/liter	72%	62%	NS
B2M > 5.5 mg/liter	7%	17%	NS
Lactate dehydrogenase ≥ 240 IU/liter	18%	24%	NS
Albumin < 35 g/liter	21%	35%	NS
Hemoglobin < 10 g/dl	*10%^	*32%^	*P = .01*
C-reactive protein ≥ 5 mg/liter	38%	36%	NS

	CCR2^high			CCR2^low
Staging	I	II	III	I	II	III
Salmon and Durie	10%	3%	87%	11%	17%	72%
	NS

When the percentages were statistically significantly different with a Chisquare test (P ≤ .05), the data are shown in italic.

Table 1. Clinical data of the CCR2high and CCR2low patients.

Table 1. Clinical data of the CCR2^high and CCR2^low patients.